We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BD Completes Clinical Trial for BD Libertas™ Wearable Injector
Product News

BD Completes Clinical Trial for BD Libertas™ Wearable Injector

BD Completes Clinical Trial for BD Libertas™ Wearable Injector
Product News

BD Completes Clinical Trial for BD Libertas™ Wearable Injector


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "BD Completes Clinical Trial for BD Libertas™ Wearable Injector"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BD (Becton, Dickinson and Company), a global medical technology company, has announced the completion of a 50-subject human clinical trial with the BD Libertas™ Wearable Injector.

The injector is a subcutaneous drug delivery system, currently in development, that is designed to require no patient assembly and deliver biologics with viscosities up to 50 cP in 2-5 mL and 5-10 mL configurations.

The BD independently sponsored and conducted study was designed to evaluate the performance of the 5 mL BD Libertas device in human subjects, including tissue effects, skin reactivity and patient acceptance. The results are expected to be announced early 2020.

The study represents the most recent in a series of over 50 BD conducted pre-clinical and clinical studies intended to measure the performance of the BD Libertas™ Wearable Injector, demonstrate the feasibility of 2-10 mL biologic injections into subcutaneous tissue and characterize tissue response to large volume injections in human and animal subjects.


Advertisement